|
|
|
Volumn 5, Issue 2, 2007, Pages 79-81
|
|
RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
CISPLATIN;
MONOCLONAL ANTIBODY;
ARTICLE;
CANCER STAGING;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
HEAD AND NECK TUMOR;
HUMAN;
INTENSITY MODULATED RADIATION THERAPY;
METHODOLOGY;
MULTIMODALITY CANCER THERAPY;
PHASE 3 CLINICAL TRIAL;
RADIATION DOSE FRACTIONATION;
RANDOMIZED CONTROLLED TRIAL;
SQUAMOUS CELL CARCINOMA;
STANDARD;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ANTINEOPLASTIC PROTOCOLS;
CARCINOMA, SQUAMOUS CELL;
CISPLATIN;
COMBINED MODALITY THERAPY;
DISEASE PROGRESSION;
DOSE FRACTIONATION;
HEAD AND NECK NEOPLASMS;
HUMANS;
NEOPLASM STAGING;
RADIOTHERAPY, INTENSITY-MODULATED;
|
|
EID: 34249844717
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (27)
|
|
References (0)
|